TNB Tech Minute: Meta’s Hit New AI Agent Is Facing Backlash
episodeTranscript
jump: chapters · speakers · find in transcriptTranscript
Transcript generated automatically by AI and may contain errors.
What is the overall focus of today’s TNB Tech Minute episode?
This episode is brought to you by Hard Lessons, a podcast from Morgan Stanley. Some investing lessons only become clear after you see how a call plays out. On Hard Lessons, iconic investors sit down with Morgan Stanley leaders to go behind the scenes on the critical moments, both successes and setbacks that shaped who they are today. Watch or listen to Hard Lessons wherever you get your podcasts.
Here's your morning TNB Tech Minute for Wednesday, September 23rd.
Why is Meta’s new Muse AI agent generating both hype and privacy concerns?
I'm Danny Lewis for The Wall Street Journal. Meta's new AI agent appears to be a hit with users and investors, but it's already facing scrutiny over privacy concerns. Though Meta says each of its Muse agents run on their own secure, dedicated computer, analysts say a major hack or incidence of agents going rogue with users' logins or credit cards could cast a negative light on the industry.
How is Amazon responding to Muse’s ability to shop on its platform?
Meanwhile, Amazon has blocked Muse from accessing its site and purchasing items for its users. The online shopping giant says it wasn't made aware of in advance that Muse would be accessing its store and that it didn't authorize the activity. Meta declined to comment on Amazon's action.
What does the valuation surge of Inveda Biosciences mean for AI‑driven drug discovery?
Elsewhere in AI, the journal exclusively reports that Inveda Biosciences, which uses the technology to streamline early-stage drug discovery, has doubled its valuation to about $2 billion. The financing will help Inveda fund later-stage human trials. The company has an experimental daily pill designed to help patients maintain weight loss after discontinuing GLP-1 medications and is also testing drugs for atopic dermatitis and inflammatory bowel disease. And a Finnish defense company is seeking $344 million by going public in Helsinki.
Why is Finnish defense firm Sensofusion seeking a €344 million IPO and what markets will it target?
Sensofusion, which makes anti-drone software, has a contract with the U.S. Marine Corps and has deployed its technology in both Ukraine and the Middle East. The company says three pension insurance companies and a fund management group have committed €170 million to anchor the IPO. Proceeds will be used to develop the group's technology and to expand production and testing into different markets. And that's your T&B Tech Minute. We'll be back this afternoon with more.
This episode is brought to you by Hard Lessons, a podcast from Morgan Stanley. Some investing lessons only become clear after you see how a call plays out. On Hard Lessons, iconic investors sit down with Morgan Stanley leaders to go behind the scenes on the critical moments, both successes and setbacks that shaped who they are today. Watch or listen to Hard Lessons wherever you get your podcasts.
No segments match your search.
Select any passage to copy it with its citation or turn it into a shareable card.
Chapters
5 chapters
1
What is the overall focus of today’s TNB Tech Minute episode?
0:01–0:31
2
Why is Meta’s new Muse AI agent generating both hype and privacy concerns?
0:31–0:54
3
How is Amazon responding to Muse’s ability to shop on its platform?
0:54–1:10
4
What does the valuation surge of Inveda Biosciences mean for AI‑driven drug discovery?
1:10–1:43
5
Why is Finnish defense firm Sensofusion seeking a €344 million IPO and what markets will it target?
1:43–2:33
Speakers
1 identifiedMore from WSJ Tech News Briefing
TNB Tech Minute: DoorDash Settles NYC Investigation Into Minimum-Pay Law Compliance
TNB Tech Minute: Alibaba Unveils New AI Chip
Polymarket’s Rush to Grow at All Costs
TNB Tech Minute: Meta’s Stock Soars as New AI Agent Gathers Steam
TNB Tech Minute: Bitcoin Surges Above $85,000
AI Therapists Are Here. Are They Safe?